Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial

BACKGROUND: Cost and supply constraints are key challenges in the use of inactivated polio vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising option, and establishing its effectiveness in the target population is a crucial milestone in developing IPV-Al. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Luis, Pedersen, Rasmus S, Peña, Lourdes, Olsen, Klaus J, Andreasen, Lars V, Kromann, Ingrid, Nielsen, Pernille I, Sørensen, Charlotte, Dietrich, Jes, Bandyopadhyay, Ananda S, Thierry-Carstensen, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483484/
https://www.ncbi.nlm.nih.gov/pubmed/28454674
http://dx.doi.org/10.1016/S1473-3099(17)30177-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483484/
https://www.ncbi.nlm.nih.gov/pubmed/28454674
http://dx.doi.org/10.1016/S1473-3099(17)30177-9

Ejemplares similares